Science Park
2 Snunit St. POB 455
Karmiel 2161401
Israel
972 4 902 8100
https://www.protalix.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 208
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Dror Bashan | President, CEO & Director | 1.38M | N/A | 1967 |
Mr. Eyal Rubin M.B.A. | Senior VP, CFO, Treasurer & Corporate Secretary | 686.78k | N/A | 1976 |
Mr. Yaron Naos | Senior Vice President of Operations | 513.82k | N/A | 1964 |
Ms. Yael Fellous | Vice President of Human Resources | N/A | N/A | N/A |
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
Protalix BioTherapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 5. The pillar scores are Audit: 4; Board: 8; Shareholder Rights: 1; Compensation: 8.